tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetate

We are tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetate CAS:124752-23-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetate
CAS.NO:124752-23-4
Synonyms:tert-butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl]acetate
Molecular Formula:C13H22O5
Molecular Weight:258.31100
 
Physical and Chemical Properties:
Density:1.073
Boiling point:320.344ºC
Flash point:140.583ºC
Index of Refraction:1.47
 
Specification:
Appearance:Slight brown or brown liquid
Assay:≥98.0%
Moisture:≤0.5%
Total imprities:≤2.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediates of Rosuvastatin Calcium

tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetate


Related News: The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).(4-([1,1-biphenyl]-4-yl(phenyl)amino)phenyl)boronic acid CAS:1084334-86-0 Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.2,5-dibromothiophene-3,4-dicarboxylic acid The API is not made by only one reaction from the raw materials but rather it becomes an API via several chemical compounds.2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethanamine CAS:78441-62-0 Corden Pharma group companies offer contract development and contract manufacturing for advanced pharmaceutical intermediates, APIs, and drug product formulations with more than 1,500 individuals supporting their customers with specialized technologies in all international markets.“CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Related Products
Product Name
Triacetoxyethylsilane View Details
2-Fluoro-3-methylaniline View Details
1,8-Dichlorooctane View Details
2-(Trifluoromethoxy)benzaldehyde manufacturer 2-Bromo-4-fluoronitrobenzene manufacturer (3,3,3-Trifluoropropyl)Methyldichlorosilane manufacturer Bis(2-methoxyethyl)aminosulfur trifluoride manufacturer N-Boc-N-methyl-D-phenylalanine manufacturer